Novartis AG (NVS)
After hours:
| Previous Close | 82.51 |
| Open | 83.19 |
| Bid | 83.12 x 1000 |
| Ask | 84.08 x 1000 |
| Day's Range | 82.72 - 83.69 |
| 52 Week Range | 74.09 - 94.26 |
| Volume | |
| Avg. Volume | 2,116,822 |
| Market Cap | 177.584B |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | 26.62 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.47 (4.16%) |
| Ex-Dividend Date | Mar 09, 2023 |
| 1y Target Est | N/A |
- GlobeNewswire
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulationSandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competition Basel, March 21, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimil
- GlobeNewswire
Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusionAll children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walkingTo date, more than 3,000 children with spinal muscular atrophy have been treated with Zolgensma across clinical trials, managed access programs and in the commercial setting1 Additionally, children wi
- GlobeNewswire
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months mPFS for standard of care1,2 Approval also received for liquid formulation options for ease of administration across multiple approved indicationsTafinlar + Mekinist is now approved in six indications across multiple BRAF V600E solid tumors, including melanoma, thyroid cancer and lung cancer1,2 Basel,
